Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

PJ Online | News | Growth factor may help Crohn’s

Home > PJ (current issue) > News / NewsCentre | Search

PJ Online homeThe Pharmaceutical Journal
Vol 274 No 7353 p703
11 June 2005

This article
Reprint   Photocopy

  Acrobat Reader


News summary


Growth factor may help Crohn’s

Severity of Crohn’s disease may be decreased by a haematopoietic growth factor.

Researchers found that administering sargramostim 6µg/kg/day topatients with active Crohn’s disease decreased disease severity and improvedthe patients’ quality of life (New England Journal of Medicine 2005;352:2193).

Back to Top


©The Pharmaceutical Journal

Citation: The Pharmaceutical Journal URI: 20014923

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

RPS publications

Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.

Visit rpharms.com

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Rate
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.